L-carnitine in Modulating Pain and Inflammation in Rheumatoid Arthritis

The Use of L-carnitine in Modulating Pain and Inflammation in Rheumatoid Arthritis Patients

This study aims at evaluating the possible efficacy and safety of L-carnitine in rheumatoid arthritis via targeting Jak/STAT pathway and TGF-β1

Inclusion Criteria:

• Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) 2010 criteria (9) i.e., 28 joints disease activity score (DAS-28) >2.6.
• Patients receive the conventional DMARDs
• Both sexes.
• Age range between 18 and 70 years old.

Exclusion Criteria:

• Patients with heart disease (congestive heart failure, arrhythmia, hypertension, ischemic heart diseases), diabetes, active infection, other illness except rheumatoid arthritis.
• Patients with renal and hepatic dysfunction.
• Patients receiving biological DMARDs.
• Patients receiving oral prednisolone greater than 15 mg/day.
• Patients with hypersensitivity to study medications.
• Patients using antioxidants.
• Pregnant and lactating females.